Thomas Helleday Ph.D.
Research Themes
Divisional Themes
- Cancer and Haematology
Group Members
- Dr Christina Bauerschmidt, Postdoc
- Daniel Ebner, Lab Manager
- Dr Esther Edlundh-Rose, Research Manager
- Dr Bastiaan Evers, Postdoc
- Dr Ponnari Gottipati, Postdoc
- Robert Latusek, DPhil student
- Dr Cecilia Lundin, Senior Postdoc
- Guy Kingham, DPhil student
- Diana Muftic, 2nd yr DPhil Student
- Dr Nils Nicolay, DPhil student
- Nicholas Pedley, DPhil Student
- Dr Eva Petermann, Postdoc
- Dr Joyce Solomons, Clinical Fellow
- Dr Navita Somaiah, DPhil student
- Armin Thalshammer, DPhil student
Selected Bibliography
- Al-Minawi Ali Z, Saleh-Gohari Nasrollah, and Helleday Thomas (2008) The ERCC1/XPF endonuclease is required for efficient single-strand annealing and gene conversion in mammalian cells. Nucleic Acids Res, 36(1):1-9.
- Gottipati Ponnari, Cassel Tobias N, Savolainen Linda, and Helleday Thomas (2008) Transcription-associated recombination is dependent on replication in Mammalian cells. Mol Cell Biol, 28(1):154-64.
- Helleday Thomas, Petermann Eva, Lundin Cecilia, Hodgson Ben, and Sharma Ricky A (2008) DNA repair pathways as targets for cancer therapy. Nat Rev Cancer, 8(3):193-204.
- Helleday Thomas, Petermann Eva, Lundin Cecilia, Hodgson Ben, and Sharma Ricky A (2008) DNA repair pathways as targets for cancer therapy. Nat Rev Cancer, 8(3):193-204.
- Helleday Thomas, Petermann Eva, Lundin Cecilia, Hodgson Ben, and Sharma Ricky A (2008) DNA repair pathways as targets for cancer therapy. Nat Rev Cancer, 8(3):193-204.
| Web | Personal Website |
|---|---|
| thomas.helleday@rob.ox.ac.uk | |
| Tel | +44 (0) 1865 617324 |
Prof Thomas Helleday
The primary goal of the DNA Damage Signalling Group is to exploit tumour defects for targeted treatment of cancer. Virtually all cancers have a defect the DNA damage response, by mutations in tumour suppressor genes. The defect in DNA damage signalling or repair weakens the ability of the cancer cell to properly replicate DNA, resulting in genetic instability that drives cancer progression. In this project we uncover cancer specific signalling and repair pathways that are targeted for novel anti-cancer treatments. The project involves identification of DNA lesions formed during replication and characterisation of DNA damage signalling and repair pathways activated by these lesions. The group is engaged in understanding basic concepts of DNA damage signalling and repair as well as conducting pre-clinical trials, to translate our basic discoveries to the clinic.
For more information on our research, please visit www.helleday.org
Biography
Education
1999 Ph.D.
Stockholm University
Sweden
1996 B.Sc. in Business Administration and Economics
Stockholm University
Sweden
1995 M.Sc. in Molecular Biology
Stockholm University
Sweden
Appointments
2007 - Senior Group Leader
Radiation Oncology & Biology
University of Oxford
2006 - Professor in Molecular Genetics
Department of Genetics, Microbiology & Toxicology
Stockholm University, Sweden
2006 Professor in Cancer Genetics
Institute for Cancer Studies
University of Sheffield
2000 - 2006 Lecturer
Institute for Cancer Studies
University of Sheffield
Awards Training and Qualifications
- 2006 AstraZeneca Young Scientist Frank Rose Award, British Association for Cancer Research
- 2005 The Eppendorf-Nature Young European Investigator Award
- 2005 European Environmental Mutagen Society Young Scientist Award
